TherapeuticsMD Q3 2026: $741K Nine-Month Profit, But Going Concern Warning Persists
TXMD sits 31% above its 52-week low of $1.43 on elevated volume (2.1× avg).
Summary
TherapeuticsMD posted $741K of nine-month 2026 net income and $10.4M of cash, but reiterated a going concern warning tied to Mayne royalty risk and an unresolved net working capital dispute. IMVEXXY generics are settled out to 2032.
Key Events · Earnings and Guidance · TXMD
-
Q3 Net Income $501K, Nine-Month $741K
Q3 2026 income from continuing operations was $501 thousand ($0.04 per share) versus $50 thousand a year earlier; nine-month net income reached $741 thousand versus $50 thousand.
-
Going Concern Warning Reiterated
Management states substantial doubt about the ability to continue as a going concern for the next twelve months, citing Mayne royalty risk, the net working capital dispute and financing needs.
-
Cash Rises to $10.4M
Cash and cash equivalents were $10,447 thousand at September 30, 2026, up from $7,483 thousand at December 31, 2025, on $2,991 thousand of operating cash flow.
-
IMVEXXY Generics Settled to 2032
Settlements with Teva (generic entry September 2, 2032) and Sun Pharma (October 21, 2032), both subject to court approval, defer generic competition on the royalty-bearing product.
Analysis · TXMD · Life Sciences
The royalty business is now profitable on paper — $741 thousand of net income over nine months versus $50 thousand a year earlier — and cash rose to $10.4 million from $7.5 million. Against that, the company repeats that there is substantial doubt about its ability to continue as a going concern for the next twelve months, hinging on Mayne Pharma royalty growth, the unresolved net working capital dispute and future financings. Two IMVEXXY patent settlements (Teva, Sun Pharma) push generic entry out to 2032, protecting the royalty stream, while a November 10 Knight amendment trims a CAD $1.0 million milestone to about CAD $0.1 million and will lower future Knight royalty revenue.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TXMD was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6M. The 52-week trading range was $1.43 to $2.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.